From this publication April 10 ---
Heartware International Inc. (NASDAQ:HTWR): Wells Fargo expects an FDA panel that will review HeartWare’s HVAD pump to be “challenging” for the company, but the firm expects the panel to recommend approval of the product. The firm estimates that the device will be launched in the U.S. in Q3 and it maintains an Outperform rating on HeartWare.
